Gene · 3799
Papers2,390
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
381 to 400 of 2,390
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Analysis of primary synchronous breast invasive ductal carcinoma and lung adenocarcinoma with next-generation sequencing: A case report. | Oncol Lett | 2023 | 36478904 | PubTator, text mining | PubMed |
| Recurrent RET fusions in fibrosarcoma-like neoplasms in adult viscera: expanding the clinicopathological and genetic spectrum. | Histopathology | 2023 | 36443894 | PubTator, text mining | PubMed |
| Response to Capmatinib in a MET Fusion-positive Cholangiocarcinoma. | Oncologist | 2023 | 36434677 | PubTator, text mining | PubMed |
| Molecular characterization of genomic breakpoints of ALK rearrangements in non-small cell lung cancer. | Mol Oncol | 2023 | 36423218 | PubTator, text mining | PubMed |
| Autophagic lysosome reformation in health and disease. | Autophagy | 2023 | 36409033 | PubTator, text mining | PubMed |
| Neoadjuvant chemotherapy is associated with an altered metabolic profile and increased cancer stemness in patients with pancreatic ductal adenocarcinoma. | Mol Oncol | 2023 | 36400567 | PubTator, text mining | PubMed |
| Enteric Neuromics: How High-Throughput "Omics" Deepens Our Understanding of Enteric Nervous System Genetic Architecture. | Cell Mol Gastroenterol Hepatol | 2023 | 36368612 | PubTator, text mining | PubMed |
| HDLBP Promotes Hepatocellular Carcinoma Proliferation and Sorafenib Resistance by Suppressing Trim71-dependent RAF1 Degradation. | Cell Mol Gastroenterol Hepatol | 2023 | 36244648 | PubTator, text mining | PubMed |
| TRIM67 drives tumorigenesis in oligodendrogliomas through Rho GTPase-dependent membrane blebbing. | Neuro Oncol | 2023 | 36215168 | PubTator, text mining | PubMed |
| Selpercatinib in Patients With RET Fusion-Positive Non-Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial. | J Clin Oncol | 2023 | 36122315 | PubTator, text mining | PubMed |
| Kinesin-1 transports morphologically distinct intracellular virions during vaccinia infection. | J Cell Sci | 2023 | 36093836 | PubTator, text mining | PubMed |
| Clinicogenomic associations in childhood Langerhans cell histiocytosis: an international cohort study. | Blood Adv | 2023 | 36083130 | PubTator, text mining | PubMed |
| Dominantly acting KIF5B variants with pleiotropic cellular consequences cause variable clinical phenotypes. | Hum Mol Genet | 2023 | 36018820 | PubTator, text mining | PubMed |
| The exosome: a review of current therapeutic roles and capabilities in human reproduction. | Drug Deliv Transl Res | 2023 | 35980542 | PubTator, text mining | PubMed |
| Selective RET inhibitors shift the treatment pattern of RET fusion-positive NSCLC and improve survival outcomes. | J Cancer Res Clin Oncol | 2023 | 35838839 | PubTator, text mining | PubMed |
Response prediction in patients with gastric and esophagogastric adenocarcinoma under neoadjuvant chemotherapy using targeted gene expression analysis and next-generation sequencing in pre-therapeutic biopsies. | J Cancer Res Clin Oncol | 2023 | 35246724 | PubTator, text mining | PubMed |
| The genomic characteristics of RET fusion positive tumors in Chinese non-small cell lung cancer (NSCLC) patients. | J Cancer Res Clin Oncol | 2023 | 35220468 | PubTator, text mining | PubMed |
| Case report: Dramatic response to alectinib in a lung adenosquamous carcinoma patient harbouring a novel CPE-ALK fusion. | Front Oncol | 2022 | 37082099 | PubTator, text mining | PubMed |
| Exceptional response to alectinib for duodenal carcinoma with ALK fusion: A case report and literature review. | Front Oncol | 2022 | 36713517 | PubTator, text mining | PubMed |
| What's new in the WHO 2022 classification of kidney tumours? | Pathologica | 2022 | 36645398 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/3799/papers?page=20